By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical late Friday announced the resignation of its CEO Wayne Kay, effective immediately. Kay also resigned as a director of the Vancouver, British Columbia-based diagnostics company.

Peter Thompson will serve as executive chairman and interim CEO, and Reponse Bio has retained an executive search firm to seek a permanent CEO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.